| Name | Title | Contact Details |
|---|---|---|
Nilay Patel |
VP, Deputy General Counsel | Profile |
Nilay Patel |
Chief Legal Officer | Profile |
OSO BioPharmaceuticals Manufacturing is a Albuquerque, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ and TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients` lives while focusing on creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular, pain and other specialty areas. Aralez`s Global Headquarters is in Ontario, Canada, the US Headquarters is planned to be in Princeton, NJ and the Irish Headquarters is in Dublin, Ireland.
Granite Recovery Centers are the New England drug and alcohol addiction treatment centers you can rely on for recovery. Call 855.712.7784 today to learn more!
NEW Health provides high quality health care services for all residents within the communities we serve. We offer a sliding fee discount for health services to those who qualify. We believe that all people deserve...
Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers. Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.